CEACAM5 and metastatic neoplasm: CEA, CA19-9, and CA125 were significantly higher in patients with metastatic disease compared with patients with localized disease (median [IQR] of metastatic vs localized for CEA, 5.8 [2.6-26.9] vs 2.2 [1.6-3.4]; difference, 3.6; 95% CI, 2.5 to 4.3 ng/mL; for CA19-9, 23.3 [10.1-77.3] vs 11.6 [6.6-19.3]; difference, 11.7; 95% CI, 8.0 to 14.7 U/mL; and for CA125, 18.5 [10.5-50.0] vs 12.5 [8.8-18.5]; difference, 6.0; 95% CI, 4.1 to 8.3 U/mL) (P < .001 for all) (Figure 1B).